Dorothy Romanus

1.3k total citations
49 papers, 881 citations indexed

About

Dorothy Romanus is a scholar working on Oncology, Hematology and Molecular Biology. According to data from OpenAlex, Dorothy Romanus has authored 49 papers receiving a total of 881 indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Oncology, 26 papers in Hematology and 21 papers in Molecular Biology. Recurrent topics in Dorothy Romanus's work include Multiple Myeloma Research and Treatments (25 papers), Protein Degradation and Inhibitors (17 papers) and Cancer Treatment and Pharmacology (11 papers). Dorothy Romanus is often cited by papers focused on Multiple Myeloma Research and Treatments (25 papers), Protein Degradation and Inhibitors (17 papers) and Cancer Treatment and Pharmacology (11 papers). Dorothy Romanus collaborates with scholars based in United States, Greece and United Kingdom. Dorothy Romanus's co-authors include Antonio Palumbo, Deborah Schrag, Paul G. Richardson, Aditya Raju, Eileen Farrelly, Marlo Blazer, Katarina Luptakova, G. Scott Gazelle, Ajai Chari and Craig C. Earle and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Annals of Surgery.

In The Last Decade

Dorothy Romanus

47 papers receiving 866 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Dorothy Romanus United States	16	507	395	356	138	132	49	881
Eric Low United Kingdom	11	496 1.0×	864 2.2×	422 1.2×	97 0.7×	41 0.3×	24	1.1k
Joan J. Ryoo United States	10	427 0.8×	572 1.4×	476 1.3×	76 0.6×	101 0.8×	19	872
Sacha Satram‐Hoang United States	16	537 1.1×	189 0.5×	262 0.7×	79 0.6×	117 0.9×	48	1.0k
Hedwig M. Blommestein Netherlands	16	296 0.6×	253 0.6×	175 0.5×	32 0.2×	113 0.9×	62	665
Stefanie Hieke Germany	9	250 0.5×	290 0.7×	195 0.5×	83 0.6×	81 0.6×	18	572
Adam E. Haynes Canada	16	257 0.5×	249 0.6×	154 0.4×	73 0.5×	339 2.6×	27	933
Senthil Rajappa India	16	286 0.6×	146 0.4×	139 0.4×	65 0.5×	184 1.4×	87	730
Marlo Blazer United States	13	386 0.8×	211 0.5×	143 0.4×	111 0.8×	131 1.0×	30	567
Kelly M. Grotzinger United States	16	180 0.4×	276 0.7×	115 0.3×	49 0.4×	129 1.0×	33	734
Jianming He United States	13	271 0.5×	488 1.2×	355 1.0×	28 0.2×	49 0.4×	53	656

Countries citing papers authored by Dorothy Romanus

Since Specialization

Citations

This map shows the geographic impact of Dorothy Romanus's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dorothy Romanus with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dorothy Romanus more than expected).

Fields of papers citing papers by Dorothy Romanus

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dorothy Romanus. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dorothy Romanus. The network helps show where Dorothy Romanus may publish in the future.

Co-authorship network of co-authors of Dorothy Romanus

This figure shows the co-authorship network connecting the top 25 collaborators of Dorothy Romanus. A scholar is included among the top collaborators of Dorothy Romanus based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dorothy Romanus. Dorothy Romanus is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Watt, Maureen, Marcus Maurer, William R. Lumry, et al.. (2023). Health-Related Quality of Life (HRQoL) in Pediatric Patients with Hereditary Angioedema (HAE) Receiving Lanadelumab: Exploratory Results From the SPRING Study. Journal of Allergy and Clinical Immunology. 151(2). AB139–AB139.

Bassel, Marielle, et al.. (2023). Retrospective chart review of transplant recipients with cytomegalovirus infection who received maribavir in the Phase 3 SOLSTICE trial: Data at 52 weeks post-maribavir treatment initiation. Antiviral Therapy. 28(5). 211921191–211921191. 2 indexed citations

Martin, Susan, et al.. (2023). Evaluating meaningful changes in physical functioning and cognitive declines in metachromatic leukodystrophy: a caregiver interview study. Journal of Patient-Reported Outcomes. 7(1). 70–70. 3 indexed citations

Kumar, Nishant, et al.. (2022). Global epidemiology of amyloid light-chain amyloidosis. Orphanet Journal of Rare Diseases. 17(1). 278–278. 47 indexed citations

Mohty, Mohamad, Wolfgang Knauf, Dorothy Romanus, et al.. (2020). Real‐world treatment patterns and outcomes in non‐transplant newly diagnosed multiple Myeloma in France, Germany, Italy, and the United Kingdom. European Journal Of Haematology. 105(3). 308–325. 10 indexed citations

Chari, Ajai, Dorothy Romanus, Antonio Palumbo, et al.. (2019). Randomized Clinical Trial Representativeness and Outcomes in Real-World Patients: Comparison of 6 Hallmark Randomized Clinical Trials of Relapsed/Refractory Multiple Myeloma. Clinical Lymphoma Myeloma & Leukemia. 20(1). 8–17.e16. 69 indexed citations

Rifkin, Robert M., et al.. (2019). Treatment Satisfaction and Burden of Illness in Patients with Newly Diagnosed Multiple Myeloma. PharmacoEconomics - Open. 4(3). 473–483. 11 indexed citations

Richardson, Paul G., Jesús F. San Miguel, Philippe Moreau, et al.. (2018). Interpreting clinical trial data in multiple myeloma: translating findings to the real-world setting. Blood Cancer Journal. 8(11). 109–109. 152 indexed citations

Chari, Ajai, Dorothy Romanus, Katarina Luptakova, et al.. (2017). Duration of Therapy (DOT) and Time to Next Therapy (TTNT) of Bortezomib, Carfilzomib and Ixazomib Combinations with Lenalidomide/Dexamethasone (VRd, KRd, IRd) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Clinical Practice in the United States Vs Clinical Trial Experience. Blood. 130. 1818–1818. 6 indexed citations

10.

Romanus, Dorothy, et al.. (2017). Treatment Satisfaction and Burden of Illness With Oral Vs Injectable Multiple Myeloma Therapy in Patients with Newly Diagnosed Disease (NDMM). Value in Health. 20(9). A454–A454. 3 indexed citations

11.

Hari, Parameswaran, Dorothy Romanus, Katarina Luptakova, et al.. (2017). The impact of age and comorbidities on practice patterns and outcomes in patients with relapsed/refractory multiple myeloma in the era of novel therapies. Journal of Geriatric Oncology. 9(2). 138–144. 28 indexed citations

12.

Romanus, Dorothy, Stephanie Cardarella, David Cutler, et al.. (2015). Cost-Effectiveness of Multiplexed Predictive Biomarker Screening in Non-Small-Cell Lung Cancer. Journal of Thoracic Oncology. 10(4). 586–594. 27 indexed citations

13.

Romanus, Dorothy, Stephanie Cardarella, David L. Cutler, et al.. (2015). Cost-Effectiveness Of Multiplexed Predictive Biomarker Screening In Non-Small Cell Lung Cancer. Value in Health. 18(3). A204–A205. 1 indexed citations

14.

Cipriano, Lauren E., Dorothy Romanus, Craig C. Earle, et al.. (2011). Lung cancer treatment costs, including patient responsibility, by disease stage and treatment modality, 1992 to 2003. Value in Health. 14(1). 41–52. 97 indexed citations

15.

Rajput, Ashwani, Dorothy Romanus, Martin R. Weiser, et al.. (2010). Meeting the 12 lymph node (LN) benchmark in colon cancer. Journal of Surgical Oncology. 102(1). 3–9. 23 indexed citations

16.

Weiser, Martin R., Anna ter Veer, J. M. Skibber, et al.. (2009). Effect of lymph node retrieval rates on the utilization of adjuvant chemotherapy in stage II colon cancer. Journal of Surgical Oncology. 100(7). 525–528. 18 indexed citations

17.

Mullins, C. Daniel, Brian Seal, Enrique Seoane‐Vazquez, et al.. (2009). Good Research Practices for Measuring Drug Costs in Cost-Effectiveness Analyses: Medicare, Medicaid and Other US Government Payers Perspectives: The ISPOR Drug Cost Task Force Report—Part IV. Value in Health. 13(1). 18–24. 22 indexed citations

18.

Schrag, Deborah, Laura Archer, X. Wang, et al.. (2007). A patterns-of-care study of post-progression treatment (Rx) among patients (pts) with advanced pancreas cancer (APC) after gemcitabine therapy on Cancer and Leukemia Group B (CALGB) study #80303. Journal of Clinical Oncology. 25(18_suppl). 4524–4524. 14 indexed citations

19.

Weinstein, Sharon M., Dorothy Romanus, Eva M. Lepisto, et al.. (2004). Documentation of Pain in Comprehensive Cancer Centers in the United States: A Preliminary Analysis. Journal of the National Comprehensive Cancer Network. 2(2). 173–180. 9 indexed citations

20.

Romanus, Dorothy, Neill Iscoe, Carlo DeAngelis, Neil H. Shear, & Thomas R. Einarson. (2004). Cost analysis of secondary prophylaxis with oral clodronate versus pamidronate in metastatic breast cancer patients. Supportive Care in Cancer. 12(12). 844–851. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact